Skip to main content
Premium Trial:

Request an Annual Quote

GeneWiz, Beijing ACCB Biotech Partner on NGS-based Tests for Clinical Space

NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.

The firms are partnering to develop, validate, and commercialize genetic tests "that deliver clinically relevant, medically actionable results," they said. GeneWiz will develop and validate genetic testing methods that ACCB will then qualify and register. Using those methods, it will then produce diagnostic kits.

"Through this collaboration, we have the opportunity to accelerate the delivery of GeneWiz's existing rich pipeline of next-generation clinical tests for genetic diseases, risk assessment, and pharmacogenomics, such as OncoGxOne and PGxOne, as well as for non-invasive cancer detection," GeneWiz Vice President of Translational Genomics Guanghui Hu said in a statement.

Last month, GeneWiz announced its entry into the clinical sequencing and personalized medicine space with two gene panels to help guide targeted cancer therapy, as Clinical Sequencing News reported at the time.

ACCB develops molecular cancer detection and diagnostic technologies. Its technology offerings include EnzymAct and BiomarkXP. EnzymAct is a kit designed for non-invasive first-line cancer screening, high-risk population identification, and recurrence monitoring, the Beijing-based company said on its website. Biomark XP is a real-time PCR-based service platform for analyzing cancer gene mutation, expression, and amplification.

Financial and other terms of the deal were not disclosed.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.